[Basic stages of organizing antineoplastic chemotherapy in Russia. Role of the Russian Oncological Scientific Center named for N. N. Blokhina, Russian Academy of Medical Sciences].

The paper outlines the history of cancer chemotherapy in our country, starting with the 1950s marked by the first studies made by L. F. Larionov to design cancer chloroethylamine drugs and by studies by N.

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.

Purpose: A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a doubling of the epirubicin dose intensity.

Patients And Methods: Four hundred fifty-six patients were randomised to receive either epirubicin 100 mg/m2 or 50 mg/m2 in combination with 5-FU (500 mg/m2) and cyclophosphamide (500 mg/m2) (FEC 100 vs. FEC 50) i.